Literature DB >> 21620714

Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.

Nikunj M Shukla1, Subbalakshmi S Malladi, Victor Day, Sunil A David.   

Abstract

Toll-like receptors (TLR) -7 and -8 are thought to play an important role in immune activation processes underlying the pathophysiology of HIV and several clinically important autoimmune diseases. Based on our earlier findings of TLR7-antagonistic activity in a 3H imidazoquinoline, we sought to examine a pilot library of 3H imidazoquinolines for dual TLR7/8 antagonists, since they remain a poorly explored chemotype. 2D-NOE experiments were employed to unequivocally characterize the compounds. A quinolinium compound 12, bearing p-methoxybenzyl substituents on N3 and N5 positions was identified as a lead. Compound 12 was found to inhibit both TLR7 and TLR8 at low micromolar concentrations. Our preliminary results suggest that alkylation with electron-rich substituents on the quinoline N5, or conversely, elimination of the fixed charge of the resultant quaternary amine on the quinolinium may yield more active compounds.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620714      PMCID: PMC3114175          DOI: 10.1016/j.bmc.2011.04.052

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

2.  Alternating 2'-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist.

Authors:  Svetlana Hamm; Eicke Latz; Doris Hangel; Thomas Müller; Philipp Yu; Douglas Golenbock; Tim Sparwasser; Hermann Wagner; Stefan Bauer
Journal:  Immunobiology       Date:  2009-10-25       Impact factor: 3.144

Review 3.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

Review 4.  Toll-like receptors, endogenous ligands, and systemic autoimmune disease.

Authors:  Ian R Rifkin; Elizabeth A Leadbetter; Liliana Busconi; Gregory Viglianti; Ann Marshak-Rothstein
Journal:  Immunol Rev       Date:  2005-04       Impact factor: 12.988

5.  Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.

Authors:  Hiroaki Hemmi; Tsuneyasu Kaisho; Osamu Takeuchi; Shintaro Sato; Hideki Sanjo; Katsuaki Hoshino; Takao Horiuchi; Hideyuki Tomizawa; Kiyoshi Takeda; Shizuo Akira
Journal:  Nat Immunol       Date:  2002-01-22       Impact factor: 25.606

Review 6.  Role for toll-like receptors in autoimmune disease: the example of systemic lupus erythematosus.

Authors:  Christophe Richez; Patrick Blanco; Ian Rifkin; Jean-François Moreau; Thierry Schaeverbeke
Journal:  Joint Bone Spine       Date:  2010-10-18       Impact factor: 4.929

7.  Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7.

Authors:  Nikunj M Shukla; Cole A Mutz; Rehman Ukani; Hemamali J Warshakoon; David S Moore; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2010-09-21       Impact factor: 2.823

8.  Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Authors:  Marie-Laure Santiago-Raber; Isabelle Dunand-Sauthier; Tianfu Wu; Quan-Zhen Li; Satoshi Uematsu; Shizuo Akira; Walter Reith; Chandra Mohan; Brian L Kotzin; Shozo Izui
Journal:  J Autoimmun       Date:  2009-11-26       Impact factor: 7.094

9.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

10.  Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9.

Authors:  Dong Yu; Daqing Wang; Fu-Gang Zhu; Lakshmi Bhagat; Meiru Dai; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

View more
  15 in total

1.  Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides.

Authors:  Deepak B Salunke; Nikunj M Shukla; Euna Yoo; Breanna M Crall; Rajalakshmi Balakrishna; Subbalakshmi S Malladi; Sunil A David
Journal:  J Med Chem       Date:  2012-03-15       Impact factor: 7.446

2.  Potent adjuvantic activity of a CCR1-agonistic bis-quinoline.

Authors:  Rehman Ukani; Tyler C Lewis; Timothy P Day; Wenyan Wu; Subbalakshmi S Malladi; Hemamali J Warshakoon; Sunil A David
Journal:  Bioorg Med Chem Lett       Date:  2011-11-09       Impact factor: 2.823

3.  Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.

Authors:  Nikunj M Shukla; Cole A Mutz; Subbalakshmi S Malladi; Hemamali J Warshakoon; Rajalakshmi Balakrishna; Sunil A David
Journal:  J Med Chem       Date:  2012-01-27       Impact factor: 7.446

4.  Antibacterial activities of Groebke-Blackburn-Bienaymé-derived imidazo[1,2-a]pyridin-3-amines.

Authors:  Nikunj M Shukla; Deepak B Salunke; Euna Yoo; Cole A Mutz; Rajalakshmi Balakrishna; Sunil A David
Journal:  Bioorg Med Chem       Date:  2012-08-08       Impact factor: 3.641

5.  Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

Authors:  Hari Prasad Kokatla; Diptesh Sil; Subbalakshmi S Malladi; Rajalakshmi Balakrishna; Alec R Hermanson; Lauren M Fox; Xinkun Wang; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2013-08-15       Impact factor: 7.446

6.  Stimulation of innate immune cells by light-activated TLR7/8 agonists.

Authors:  Keun Ah Ryu; Lalisa Stutts; Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  J Am Chem Soc       Date:  2014-07-28       Impact factor: 15.419

7.  Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.

Authors:  Alex C D Salyer; Giuseppe Caruso; Karishma K Khetani; Lauren M Fox; Subbalakshmi S Malladi; Sunil A David
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

8.  Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.

Authors:  Mallesh Beesu; Giuseppe Caruso; Alex C D Salyer; Karishma K Khetani; Diptesh Sil; Mihiri Weerasinghe; Hiromi Tanji; Umeharu Ohto; Toshiyuki Shimizu; Sunil A David
Journal:  J Med Chem       Date:  2015-09-22       Impact factor: 7.446

Review 9.  Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.

Authors:  Deepender Kaushik; Arshpreet Kaur; Nikolai Petrovsky; Deepak B Salunke
Journal:  RSC Med Chem       Date:  2021-05-14

10.  Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

Authors:  Mallesh Beesu; Subbalakshmi S Malladi; Lauren M Fox; Cassandra D Jones; Anshuman Dixit; Sunil A David
Journal:  J Med Chem       Date:  2014-08-20       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.